Invention Grant
US09562076B2 Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors
有权
乙型肝炎病毒（HBV）的疏水性修饰的前衍生肽及其作为HBV和HDV进入抑制剂的用途
- Patent Title: Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors
- Patent Title (中): 乙型肝炎病毒（HBV）的疏水性修饰的前衍生肽及其作为HBV和HDV进入抑制剂的用途
-
Application No.: US12863663Application Date: 2009-01-26
-
Publication No.: US09562076B2Publication Date: 2017-02-07
- Inventor: Walter Mier , Stephan Urban
- Applicant: Walter Mier , Stephan Urban
- Applicant Address: DE Heidelberg
- Assignee: RUPRECHT-KARLS-UNIVERSITÄT-HEIDELBERG (Rektorat)
- Current Assignee: RUPRECHT-KARLS-UNIVERSITÄT-HEIDELBERG (Rektorat)
- Current Assignee Address: DE Heidelberg
- Agency: Jones Day
- Priority: WOPCT/EP2008/000591 20080125
- International Application: PCT/EP2009/000476 WO 20090126
- International Announcement: WO2009/092611 WO 20090730
- Main IPC: A61K39/29
- IPC: A61K39/29 ; C07K7/08 ; C07K14/02 ; A61P31/20 ; C07K14/005 ; A61K47/48 ; A61K39/12 ; A61K38/00
Abstract:
The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.
Public/Granted literature
Information query
